News
Navigating Challenges in Oncology: Jazz Pharmaceuticals and PharmaMar Stay Committed Despite Phase 3 Setback
In the rigorous and highly demanding landscape of oncology research, scientific progress is often non-linear. Recently, Jazz Pharmaceuticals and its partner PharmaMar announced that their Phase 3 trial evaluating Zepzelca did not meet its primary endpoint.
16 Jun 2026